(29) reported two cases of unresectable stage III NSCLC harboring BRAF V600E mutations successfully treated with a combination of dabrafenib, trametinib, and a PD-1 inhibitor as induction therapy. Here, BRAF is linked to non-small cell lung carcinoma.